Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336–43.

Article  CAS  PubMed  Google Scholar 

Hofer U. The cost of antimicrobial resistance. Nat Rev Microbiol. 2019;17:3.

Article  CAS  PubMed  Google Scholar 

O’neill J. Tackling a global health crisis: initial steps. Wellcome Trust, London. 2015. Accessed 12 Apr 2019.

World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017.

Li J, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601.

Article  CAS  PubMed  Google Scholar 

Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity,susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nang SC, Azad M, Velkov T, Zhou QT, Li J. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 2021;73:679–728.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593–656.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 2013;8:711–24.

Article  CAS  PubMed  Google Scholar 

Moffatt JH, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez CH, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–91.

Article  PubMed  Google Scholar 

Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.

Article  PubMed  Google Scholar 

Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem. 2010;53:1898–916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velkov T, et al. Teaching ‘old’ polymyxins new tricks: new-generation lipopeptides targeting gram-negative ‘superbugs’. ACS Chem Biol. 2014;9:1172–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaara M, et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother. 2008;52:3229–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J Antimicrob Chemother. 2013;68:636–9.

Article  CAS  PubMed  Google Scholar 

Vaara M, Siikanen O, Apajalahti J, Frimodt-Møller N, Vaara T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J Antimicrob Chemother. 2010;65:942–5.

Article  CAS  PubMed  Google Scholar 

Vaara M, Vaara T. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. Int J Antimicrob Agents. 2013;41:292–3.

Article  CAS  PubMed  Google Scholar 

Vingsbo Lundberg C, Vaara T, Frimodt-Møller N, Vaara M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother. 2010;65:981–5.

Article  CAS  PubMed  Google Scholar 

Tsubery H, Ofek I, Cohen S, Fridkin M. Structure activity relationship study of polymyxin B nonapeptide. Adv Exp Med Biol. 2000;479:219–22.

Article  CAS  PubMed  Google Scholar 

Roberts KD, et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat Commun. 2022;13:1625.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown P, et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect Dis. 2019;5:1645–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown P, Dawson MJ. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J Antibiot. 2017;70:386–94.

Article  CAS  Google Scholar 

de Visser PC, et al. Solid-phase synthesis of polymyxin B1 and analogues via a safety-catch approach. J Pept Res. 2003;61:298–306.

Article  PubMed  Google Scholar 

Gang D, Kim DW, Park HS. Cyclic peptides: promising scaffolds for biopharmaceuticals. Genes. 2018;9:557.

Article  PubMed  PubMed Central  Google Scholar 

Jafari MR, Yu H, Wickware JM, Lin YS, Derda R. Light-responsive bicyclic peptides. Org Biomol Chem. 2018;16:7588–94.

Article  CAS  PubMed  Google Scholar 

Katsuma N, et al. Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem Pharm Bull. 2009;57:332–6.

Article  CAS  Google Scholar 

Sakura N, et al. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull Chem Soc Jpn. 2004;77:1915–24.

Article  CAS  Google Scholar 

Okimura K, Ohki K, Sato Y, Ohnishi K, Sakura N. Semi-synthesis of polymyxin B (2–10) and colistin (2–10) analogs employing the Trichloroethoxycarbonyl (Troc) group for side chain protection of alpha, gamma-diaminobutyric acid residues. Chem Pharm Bull. 2007;55:1724–30.

Article  CAS  Google Scholar 

Kubin CJ, et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65:80–7.

Article  PubMed  Google Scholar 

Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65:2231–7.

Article  CAS  PubMed  Google Scholar 

Yun B, et al. Cellular uptake and localization of polymyxins in renal tubular cells using rationally designed fluorescent probes. Antimicrob Agents Chemother. 2015;59:7489–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M. Molecular mechanisms of colistin-induced nephrotoxicity. Molecules. 2019;24:653.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Espinel-Ingroff A, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:5243–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jangra M, et al. Tridecaptin M, a new variant discovered in mud bacterium, shows activity against colistin- and extremely drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63:e00338–19.

Article  CAS  PubMed  PubMed Central  Google Scholar